Document is current

Article History

Received: 9 December 2022

Accepted: 7 June 2023

First Online: 31 July 2023

Declarations

:

: Peter Siersema receives unrestricted grants from Pentax (Japan), Norgine (UK), Motus GI (USA), MicroTech (China), and The eNose Company (The Netherlands), and is in the advisory board of Motus GI (USA) and Boston Scientific (USA). All fees paid to the institute and unrelated to the present study. Camiel Rosman has received research grants from Johnson & Johnson and Medtronic. All fees paid to the institute and unrelated to the present study. Nicole C.T. van Grieken reported receiving grants from the Dutch Cancer Society, Cancer Center Amsterdam, and The Netherlands Organisation for Health Research and Development, and serving on an advisory board for Bristol-Myers Squibb and Merck Sharp and Dohme. All fees paid to the institute and unrelated to the present study. Mark I. van Berge Henegouwen is consultant for Mylan, Johnson & Johnson, Alesi Surgical, BBraun, and Medtronic, and received unrestricted research grants from Stryker. All fees paid to the institute and unrelated to the present study. Dr. Maarten F. Bijlsma received research funding from Celgene and Lead Pharma and has acted as a consultant for Servier. All fees paid to the institute and unrelated to the present study. Rob HA Verhoeven has received research grants from Roche and Bristol-Myers Squibb. All fees paid to the institute and unrelated to the present study. M. Verheij reported receiving grants from the Dutch Cancer Society, the Dutch Colorectal Cancer Group, and Hoffmann La Roche. All fees paid to the institute and unrelated to the present study. Prof. Dr. Hanneke W. M. van Laarhoven has served as a consultant or in an advisory role for: Amphera, AstraZeneca, Beigene, BMS, Daiichy-Sankyo, Dragonfly, Eli Lilly, MSD, Nordic Pharma, Servier. Prof. dr. Hanneke W. M. van Laarhoven has received research funding and/or medication supply from: Bayer, BMS, Celgene, Janssen, Incyte, Eli Lilly, MSD, Nordic Pharma, Philips, Roche, Servier. Prof. Dr. Hanneke W. M. van Laarhoven served a speaker role for: Astellas, Benecke, Daiichy-Sankyo, JAAP, Medtalks, Novartis, Travel Congress Management B.V. Prof. Dr. Hanneke W. M. van Laarhoven is employed and performs a managing role at: Amsterdam UMC, The Netherlands (Head of the Department of Medical Oncology) Honorary: ESMO (Chair Upper GI Faculty). None of these parties were involved in the current study. All other authors have no conflict of interest to report.